Chemotheraphy

Phase 3Small molecule

AAlliance for Clinical Trials in Oncology

Chemotheraphy is one of 26 small molecule programs targeting Oral Mucositis. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Oral MucositisRecruiting

Oral MucositisPhase 3

Recruiting

Competition

Competitive Landscape

26 competitors in Oral Mucositis

#DrugCompanyPhaseTrials

Thalomid

Bristol-Myers Squibb

Approved

—2

MS Contin

HHikma Pharmaceuticals LLC

Approved

2 3

Alka-Seltzer

AAbbott

Approved

1 4

Levaquin

WWim Janssens

Approved

1 5

Catapres

Boehringer Ingelheim

Approved

—6

Heparin Sodium

BBaxter Healthcare Corporation

Approved

—7

Peridex

DDexcel Pharma Technologies Ltd.

Approved

—8

Betadine

BBecton, Dickinson and Company

Mycostatin

Acetadote

AArbor Pharmaceuticals, Inc.

Approved

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2031

Phase 3Recruiting

Oral Mucositis

NCT06992427

Clinical

Trials by Indication[1]

Oral Mucositis1 trial

High-dose Prophylactic Gabapentin (HOPE) vs. Placebo to Prevent Opioid Use for Oral Mucositis Pain During Concurrent Chemoradiation for Head and Neck Cancer

Recruiting·AAlliance for Clinical Trials in Oncology·Phase 3·NCT06992427·228 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Chemotheraphy. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Chemotheraphy compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Chemotheraphy. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Alliance for Clinical Trials in Oncology company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: AAlliance for Clinical Trials in Oncology

Chemotheraphy

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2031

Trials by Indication[1]

Oral Mucositis1 trial

References

Drug Info

Quick Facts

Related News